May 9, 2022
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
May 5, 2022
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees
May 5, 2022
Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
May 4, 2022
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card
April 26, 2022
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
April 20, 2022
Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
April 5, 2022
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders
April 4, 2022
Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions
March 30, 2022
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future
March 24, 2022
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
Displaying 71 - 80 of 139